Home Companies Catalysts Deep Dives
Biktarvy bictegravir/emtricitabine/tenofovir alafenamide APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaInfectious Disease
Launch2018-02-07
US LOE2036-04-01
Peak Sales Est$15000M
Formulations[{"id":"biktarvy-tablet","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily","is_primary"
Companies
GILD (ORIGINATOR)100%
Mechanism: Integrase strand transfer inhibitor (INSTI)
Expert: Inhibits HIV-1 integrase, preventing viral DNA integration into host genome.
Everyday: Blocks HIV from inserting its genetic material into human cells.
Targets: ["HIV INTEGRASE"]
Revenue History
PeriodRevenue ($M)
2023$11,871M
2024$13,423M
2025$14,200M
Q1 2025$3,312M
Q2 2025$3,368M
Q3 2025$3,686M
Q4 2025$4,000M
Programs (1)
IndicationStageKey StudyRegional Status
HIV-1 treatmentAPPROVEDGS-US-380-1489/1490[{"stage":"APPROVED","region":"US","approval_date":"2018-02-07"},{"stage":"APPRO
Notes
Market-leading HIV single-tablet regimen. #1 prescribed HIV treatment in US/EU.
Data from Supabase · Updated 2026-03-24